Evaluation the effectiveness of varenicline on smoking cessation
Objective To explore the effectiveness of varenicline on smoking cessation.Methods In this cross-sectional study,a total of 318 tobacco-dependent adults with complete medical record were included from January 2018 to June 2023 in the First Affiliated Hospital of Soochow University.All the patients received smoking cessation advices and exhaled carbon monoxide(eCO)detection on initial visit and 3 months later.According to whether they received varenicline,the participants were divided into smoking cessation advices(SCA)group(126 cases)and varenicline(VAR)group(192 cases).The follow-up period was≥3 months.Quit smoking for at least 3 months was regarded as successful smoking-cessation.Results eCO levels on enrollment and 3 months later for SCA group and VAR group were(11.5±4.8)vs(11.8±4.3)ppm and(7.8±3.6)vs(7.3±4.3)ppm(P=0.550,0.239).eCO levels of SCA group and VAR group decreased significantly 3 months later(t=7.293,11.920,both P<0.001).Participants in VAR group had significantly higher odds of abstinence than those in SCA group(40.6%vs 28.6%,x2=4.806,P=0.028).After quit smoking successfully,eCO levels decreased from(15.5±5.6)and(13.9±5.1)ppm to(3.6±2.4)and(3.5±2.5)ppm(t=17.580,27.180,both P<0.001)for SCA group and VAR group respectively.Conclusion Varenicline usaee can increase the abstinence rates of tobacco-dependent adults.